Cite
Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
MLA
Shen, Chiung-Chyi, et al. “Both P53 Codon 72 Arg/Arg and pro/Arg Genotypes in Glioblastoma Multiforme Are Associated with a Better Prognosis in Bevacizumab Treatment.” BMC Cancer, vol. 20, no. 1, July 2020, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s12885-020-07210-8.
APA
Shen, C.-C., Cheng, W.-Y., Lee, C.-H., Dai, X.-J., Chiao, M.-T., Liang, Y.-J., Hsieh, W.-Y., Mao, T.-F., Lin, G.-S., Chen, S.-R., Liu, B.-S., & Chen, J.-P. (2020). Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer, 20(1), 1–13. https://doi.org/10.1186/s12885-020-07210-8
Chicago
Shen, Chiung-Chyi, Wen-Yu Cheng, Chung-Hsin Lee, Xue-Jun Dai, Ming-Tsang Chiao, Yea-Jiuen Liang, Wan-Yu Hsieh, et al. 2020. “Both P53 Codon 72 Arg/Arg and pro/Arg Genotypes in Glioblastoma Multiforme Are Associated with a Better Prognosis in Bevacizumab Treatment.” BMC Cancer 20 (1): 1–13. doi:10.1186/s12885-020-07210-8.